1, recommended for all HSCT recipients; 2, recommended for patients with ongoing GVHD or immunosuppression; +, recommended for abnormal testing in a previous time period or for new signs/symptoms.
* including inquiry about school/work attendance, need for social support/disability pension, financial toxicity.
References
1 1. Institute of Medicine, National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition: An American Society of Clinical Oncology and Institute of Medicine Symposium. Washington, DC: The National Academies Press, 2006.
2 2. Denzen EM, Preussler JM, Murphy EA, et al. Tailoring a survivorship care plan: patient and provider preferences for recipients of hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(3):562–569.
3 3. Majhail NS, Murphy E, Laud P, et al. Randomized controlled trial of individualized treatment summary and survivorship care plans for